Targeted therapy in head and neck cancer: State of the art 2007 and review of clinical applications

Cancer

Volumn 112, Issue 12, 2008, Pages 2635-2645

  Langer, Corey J ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Cetuximab; Epidermal growth factor receptor; Monoclonal anti bodies; Platinum refractory squamous cell carcinoma of the head and neck; Targeted therapies

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; LAPATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR;

ACNE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; DYSPHAGIA; ENZYME INHIBITION; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEAD AND NECK CANCER; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RASH; REVIEW; SKIN EXFOLIATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; HEAD AND NECK TUMOR;

ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 46049093437     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23521     Document Type: Review

References (108)

1. Psyrri A, Fountzilas G. Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region. Med Oncol. 2006;23: 1-15.
2. Tepperman BS, Fitzpatrick PJ. Second respiratory and upper digestive tract cancers after oral cancer. Lancet. 1981;2:547-549.
3. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004;22:1743-1752.
4. Olmi P, Crispino S, Fallai C, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy - a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55:78-92.
5. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
6. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II Trial 99-14. J Clin Oncol. 2005;23:3008-3015.
7. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst. 2004; 96:1714-1717.
8. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568-5577.
9. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E 1393. J Clin Oncol. 2001;19:1088-1095.
10. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992; 10:257-263.
11. Gibson MK, Li Y, Murphy B, et al. for the Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562-3567.
12. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
13. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-2098.
14. Huguenin P, Beer KT, Allai A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22:4665-4673.
15. Jeremic B, Milicic B, Dagovic A, Vaskovic Z, Tadic L. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2004;22:3540-3548.
16. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161-1171.
17. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-955.
18. Bourhis J, Armand C, Pignon JP. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy [abstract]. J Clin Oncol. 2004;22. Abstract 5505.
19. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
20. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952.
21. Calais G, Alfonsi M, Bardet E, et al. Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma: final results of the 94-01 GORTEC randomized study [abstract]. Int J Radiat Oncol Biol Phys. 2001;519(suppl 1):1-2. Abstract 2.
22. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head an neck cancer: a meta-analysis. Lancet. 2006;368:843-854.
23. Ozyigit G, Yang T, Chao KS. Intensity-modulated radiation therapy for head and neck cancer. Curr Treat Options Oncol. 2004;5:3-9.
24. Mendenhall WM, Hinerman RW, Amdur RJ, et al. Postoperative radiotherapy for squamous cell carcinoma of the head and neck. Clin Med Res. 2006;4:200-208.
25. Cozzi L, Fogliata A, Bolsi A, et al. Three-dimensional conformal versus intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys. 2004;58:617-624.
26. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer. 2005;104: 1296-1303.
27. Gibson MK, Forastiere AA. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol. 2006;7:565-574.
28. Lefebvre JL. Laryngeal preservation in head and neck cancer: multidisciplinary approach. Lancet Oncol. 2006;7:747-755.
29. Hitt R, Paz-Ares L, Brandariz A, et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol. 2002;13:1665-1673.
30. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636-8645.
31. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705-1715.
32. Remenar E, Van Herpen C, Germa-Lluch J, et al. A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): final analysis of EORTC 24971 [abstract]. J Clin Oncol. 2006;24(18S). Abstract 5516.
33. Cohen EEW, Vokes EE. A phase III randomized trial of docetaxel-based induction chemotherapy in patients with N2/N3 locally advanced head and neck cancer (DeCIDE Trial). Protocol identifier NCT0011 7572. Available at: ClinicalTrials.gov. Accessed July 10, 2007.
34. Khuri F; for the Dana-Farber Cancer Institute. The Paradigm Trial. A randomized phase III trial comparing sequential therapy with TPF/chemoradiation (ST) to cisplatin-based chemoradiotherapy with accelerated concomitant boost radiotherapy (CRT) for locally advanced squamous cell cancer of the head and neck. Study DFCI1015-04; protocol 07182005.Available at: http://cancer. emory.edu/clinical/trialdetail.php?id=723&detail=full. Accessed July 10, 2007.
35. Langer CJ, Li Y, Jennings T, DeConti RC, Nair S, Cohen RB, et al. for the Eastern Cooperative Oncology Group. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer Invest. 2004;22:823-831.
36. Vermorken J, Bourhis J, Trigo M, et al. Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck refractory to first-line platinum-based therapies [abstract]. J Clin Oncol. 2005;23(suppl). Abstract 5505.
37. Lefebvre JL. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol. 2005;16(suppl6):vi7-vi12.
38. Regine WF, Valentino J, Arnold SM, et al. High-dose intraarterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2001;19:3333-3339.
39. Regine WF, Valentino J, Arnold SM, et al. A phase II study of concomitant hyperfractionated radiation therapy and double dose intra-arterial cisplatin for squamous cell carcinoma of the head and neck. Technol Cancer Res Treat. 2002;1:133-140.
40. Tsao AS, Garden AS, Kies MS, et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006;24:4163-4169.
41. Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006;6:1539-1552.
42. Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther. 2005;5:1085-1093.
43. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579-3584.
44. Christensen ME, Therkildsen MH, Hansen BL, et al. Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas. Eur Arch Otorhinolaryngol. 1992;249:243-247.
45. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579-3584.
46. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24:2666-2672.
47. Liang K, Ang KK, Milas L, et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 2003;57:246-254.
48. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-7356.
49. Pivot X, Magne N, Guardiola E, et al. Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol. 2005;41: 320-327.
50. Hitt R, Ciruelos E, Amador ML, et al. Prognostic value of the epidermal growth factor receptor (EGFR) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction therapy. Eur J Cancer. 2005; 41:453-460.
51. Milas L, Mason K, Hunter N, et al. Enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000;6:701-708.
52. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369-385.
53. Licitra L, Locati L, Bossi P. Biological agents in head and neck cancer. Ann Oncol. 2006;17(suppl 17):x45-x48.
54. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935-1940.
55. Huang S-M, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res. 2000;6:2166-2174.
56. Huang S-M, Li J, Harari P. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002;1:507-514.
57. Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2006;6:691-710.
58. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311-1318.
59. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005;280:31182-31189.
60. Hadari YR, Doody JF, Wang Y, et al. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor [abstract]. Presented at the 2004 Gastrointestinal Cancers Symposium, San Francisco, California, January 22-24, 2004. Abstract 234.
61. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 1996;19:419-427.
62. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 1999;14:451-463.
63. Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys. 2004;58:966-971.
64. Fan Z, Masui H, Altas I, et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53:4322-4328.
65. Naramura M, Gillies SD, Mendelsohn J, et al. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother. 1993; 37:343-349.
66. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Erbitux induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer. 2006;120:781-787.
67. Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
68. Lenz H-J, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24: 4914-4921.
69. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
70. Food & Drug Administration Press Release. FDA approves first head & neck cancer treatment in 45 years: data show treatment with Erbitux extends survival. FDA News. March 1, 2006. Available at: http://www.fda.gov/bbs/ topics/NEWS/2006/NEW01329.html. Accessed July 11, 2007.
71. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24:1072-1078.
72. Suntharalingam M, Taylor R, Wolf J, et al. Initial report of phase II trial of weekly cetuximab, CBDCA, paclitaxel and daily RT in patients with locally advanced SCCHN [abstract]. Presented at the Multidisciplinary Head and Neck Cancer Symposium, cosponsored by the American Society for Therapeutic Radiology and Oncology and the American Society of Clinical Oncology, Rancho Mirage, California, January 18-20, 2007. Abstract 5.
73. National Library of Medicine. Search results for various head and neck cancer trials (RTOG-0522, RTOG-0234, ECOG-3303, ECOG-E2303, and keywords bevacizumab/cetuximab, bevacizumab/chemoradiotherapy). Available at: http://www.clinicaltrials.gov/. Accessed July 11, 2007.
74. Vermorken JB, Trigo J, Hitt R, et al. Open-Label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177.
75. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5578-5587.
76. Burtness B, Goldwater MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646-8654.
77. Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy: results of a randomized phase III (EXTREME) study [abstract]. J Clin Oncol. 2007;25(suppl). Abstract 6091.
78. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther. 1999;82:207-218.
79. Magne N, Fischel JL, Dubreuil A, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer. 2002; 86:1518-1523.
80. Shintani S, Li C, Mihara M, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer. 2003;107:1030-1037.
81. Cohen EE, Haraf DJ, Stenson KM, et al. Integration of gefitinib into a concurrent chemoradiation regimen followed by gefitinib adjuvant therapy in patients with locally advanced head and neck cancer - a phase II trial [abstract]. Proc Am Soc Clin Oncol. 2005;24:501s. Abstract 5506.
82. Doss HH, Greco FA, Meluch AA, et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of the Minnie Pearl Cancer Research Network [abstract]. J Clin Oncol. 2006;24(suppl). Abstract 5543.
83. Herchenhorn D, Dias FL, Ferreira CG, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol. 2006; 24(suppl). Abstract 5575.
84. Harrington KJ, Bourhis J, Nutting CM, et al. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol. 2006;24(suppl). Abstract 5553.
85. Savvides P, Agarwala SS, Greskovich J, et al. Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2006;24(suppl). Abstract 5545.
86. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21:1980-1987.
87. Kane MA, Cohen EE, List M, et al. Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol. 2004;22(suppl). Abstract 5586.
88. Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract]. Proc Am Soc Clin Oncol. 2005;24: 507s. Abstract 5531.
89. Cohen EEW, Rosen F, Dekker A, et al. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol. 2002;21:225a. Abstract 899.
90. Health Canada/AstraZeneca. December 1, 2006 letter to healthcare professionals. Health Canada endorsed important safety information on Iressa (gefitinib): lack of survival benefit and increased incidence of tumour haemorrhage in association with IRESSA® in patients with squamous cell carcinoma of the head and neck (SCCHN). Available at: http://www.hc-sc.gc.ca. Accessed July 11, 2007.
91. Belon J, Irigoyen A, Rodriguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]. J Clin Oncol. 2005;23(suppl). Abstract 5563.
92. Kim ES, Kies M, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract]. J Clin Oncol. 2007;25(suppl). Abstract 6013.
93. Wirth LJ, Haddad RI, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:6976-6981.
94. Vokes EE, Cohen EE, Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol. 2006;24(suppl). Abstract 5504.
95. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol. 2006;24(suppl). Abstract 5568.
96. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-4380.
97. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3: 391-400.
98. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
99. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
100. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-799.
101. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
102. Wong SJ, Agha S, Milligan M. Concurrent chemotherapy practice patterns for head and neck cancer: what is standard of care [abstract]? J Clin Oncol. 2006;24(suppl). Abstract 5542.
103. Cox JD, Pajak TF, Marcial VA, et al. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313. Cancer. 1992;69:2744-2748.
104. Hansen O, Overgaard J, Hansen HS, et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol. 1997;43:47-51.
105. Ehrsson YT, Langius-Eklof A, Bark T, Laurell G. Percutaneous endoscopic gastrostomy (PEG): a long-term follow-up study in head and neck cancer patients. Clin Otolaryngol Allied Sci. 2004;29:740-746.
106. Akervall J. Genomic screening of head and neck cancer and its implications for therapy planning. Eur Arch Otorhinolaryngol. 2006;263:297-304.
107. Bonner JA, Harari PM, Giralt J, et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab [abstract]. Proc Am Soc Clin Oncol. 2006;24:282s. Abstract 5510.
108. Kies MS, Garden AS, Holsinger C, et al. Induction chemotherapy with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol. 2006;24(suppl).Abstract 5520.